Biosimilar drug treatment for inflammatory disease
Wezlana (ustekinumab-auub) has received U.S. Food and Drug Administration (FDA) approval as a biosimilar and interchangeable medication with Stelara (ustekinumab), a drug used in the treatment of various inflammatory diseases. Wezlana is now authorized to treat a range of conditions in both adult and pediatric patients, including moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis.
Both Wezlana and Stelara come with warnings about serious infections, risks of malignancies, hypersensitivity reactions, and other potential side effects. Biosimilars like Wezlana offer the potential to increase access to effective treatments while potentially reducing health care costs, providing patients and health care providers with more choices to manage these conditions effectively.